Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 8, 2015, Pages 1965-1974

  Klimas, Jan ^a   Olvedy, Michael ^a,d   Ochodnicka Mackovicova, Katarina ^a,e   Kruzliak, Peter ^b   Cacanyiova, Sona ^c   Kristek, Frantisek ^c   Krenek, Peter ^a   Ochodnicky, Peter ^a  

^a Physics and Informatics   (Slovakia)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

ACE2 Ang (1 7) Mas receptor axis; Gene expression; Hypertension; Losartan; Treatment; Ventricular hypertrophy

Indexed keywords

RATTUS;

ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; G PROTEIN COUPLED RECEPTOR; LOSARTAN; MESSENGER RNA; NITRIC OXIDE; ONCOPROTEIN; PROTO-ONCOGENE PROTEINS C-MAS-1;

ANIMAL; CARDIAC MUSCLE; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEART VENTRICLE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; MALE; METABOLISM; NEWBORN; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANIMALS, NEWBORN; FEMALE; GENE EXPRESSION REGULATION; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; LOSARTAN; MALE; MYOCARDIUM; NITRIC OXIDE; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RATS, INBRED SHR; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84938196502     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12573     Document Type: Article

References (55)

1. Nishikawa K. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens. 1998; 12: 301-9.
2. Racasan S, Hahnel B, van der Giezen DM, et al. Temporary losartan or captopril in young SHR induces malignant hypertension despite initial normotension. Kidney Int. 2004; 65: 575-81.
3. Woods LL. Fetal origins of adult hypertension: a renal mechanism? Curr Opin Nephrol Hypertens. 2000; 9: 419-25.
4. Fornes P, Richer C, Vacher E, et al. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol. 1993; 22: 305-13.
5. Svitok P, Molcan L, Vesela A, et al. Increased salt intake during early ontogenesis lead to development of arterial hypertension in salt-resistant Wistar rats. Clin Exp Hypertens. 2014; 22: 1-6.
6. Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol. 2010; 298: F1297-305.
7. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008; 93: 519-27.
8. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006; 7: 3-14.
9. Diez-Freire C, Vazquez J, Correa de Adjounian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006; 27: 12-9.
10. Ritchie RH, Schiebinger RJ, LaPointe MC, et al. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol. 1998; 275: H1370-4.
11. Suzuki H, Eguchi K, Ohtsu H, et al. Activation of endothelial nitric oxide synthase by the angiotensin II type 1 receptor. Endocrinology. 2006; 147: 5914-20.
12. Piech A, Dessy C, Havaux X, et al. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res. 2003; 57: 456-67.
13. Vaziri ND, Ni Z, Oveisi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension. 1998; 31: 1248-54.
14. Klimas J, Vaja V, Vercinska M, et al. Discrepant regulation of QT (QTc) interval duration by calcium channel blockade and angiotensin converting enzyme inhibition in experimental hypertension. Basic Clin Pharmacol Toxicol. 2012; 111: 279-88.
15. Kristek F, Malekova M, Cacanyiova S. Long-term effect of prazosin and losartan administration on blood pressure, heart, carotid artery, and acetylcholine induced dilation of cardiovascular system of young Wistar rats and SHR. Gen Physiol Biophys. 2013; 32: 235-43.
16. Jin X, Xia L, Wang LS, et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics. 2006; 6: 1948-56.
17. Braun MC, Herring SM, Gokul N, et al. Hypertensive renal disease: susceptibility and resistance in inbred hypertensive rat lines. J Hypertens. 2013; 31: 2050-9.
18. Bernstein KE. Views of the renin-angiotensin system: brilling, mimsy, and slithy tove. Hypertension. 2006; 47: 509-14.
19. Kmecova J, Klimas J. Heart rate correction of the QT duration in rats. Eur J Pharmacol. 2010; 641: 187-92.
20. Ochodnicky P, Mesarosova L, Cernecka H, et al. Pioglitazone, a PPARgamma agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. Eur J Pharmacol. 2014; 730: 51-60.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-8.
22. Woods LL, Rasch R. Perinatal ANG II programs adult blood pressure, glomerular number, and renal function in rats. Am J Physiol. 1998; 275: R1593-9.
23. Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988; 112: 805-10.
24. Pryde PG, Sedman AB, Nugent CE, et al. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993; 3: 1575-82.
25. Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43: 970-6.
26. Tan Z, Wu J, Ma H. Regulation of angiotensin-converting enzyme 2 and Mas receptor by Ang-(1-7) in heart and kidney of spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2011; 12: 413-9.
27. Zhong JC, Huang DY, Yang YM, et al. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension. 2004; 44: 907-12.
28. Meng W, Zhao W, Zhao T, et al. Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension. Am J Hypertens. 2014; 27: 775-82.
29. Higashi T, Kobayashi N, Hara K, et al. Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats. J Cardiovasc Pharmacol. 2000; 35: 564-71.
30. Kruzliak P, Novak J, Novak M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens. 2014; 27: 3-13.
31. Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis. 2013; 16: 289-95.
32. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001; 37: 767-73.
33. Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997; 99: 278-87.
34. Costa MA, Lopez Verrilli MA, Gomez KA, et al. Angiotensin-(1-7) upregulates cardiac nitric oxide synthase in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010; 299: H1205-11.
35. Dias-Peixoto MF, Ferreira AJ, Almeida PW, et al. The cardiac expression of Mas receptor is responsive to different physiological and pathological stimuli. Peptides. 2012; 35: 196-201.
36. Gomes ER, Lara AA, Almeida PW, et al. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3, 5′-cyclic monophosphate-dependent pathway. Hypertension. 2010; 55: 153-60.
37. Ishizaka N, Griendling KK, Lassegue B, et al. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension. 1998; 32: 459-66.
38. Krieger MH, Di Lorenzo A, Teutsch C, et al. Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice. Lab Invest. 2010; 90: 1573-81.
39. Asano N, Ogura T, Mimura Y, et al. Renal AT1 receptor: computerized quantification in spontaneously hypertensive rats and DOCA-salt rats. Res Commun Mol Pathol Pharmacol. 1998; 100: 171-80.
40. Samani NJ, Swales JD, Brammar WJ. A widespread abnormality of renin gene expression in the spontaneously hypertensive rat: modulation in some tissues with the development of hypertension. Clin Sci. 1989; 77: 629-36.
41. Yu H, Di Nicolantonio R. Altered age-dependent modulation of tissue renin messenger RNA levels in the spontaneously hypertensive rat. J Hypertens. 1996; 14: 871-80.
42. Liu L, Gonzalez AA, McCormack M, et al. Increased renin excretion is associated with augmented urinary angiotensin II levels in chronic angiotensin II-infused hypertensive rats. Am J Physiol Renal Physiol. 2011; 301: F1195-201.
43. Harrison-Bernard LM, Zhuo J, Kobori H, et al. Intrarenal AT(1) receptor and ACE binding in ANG II-induced hypertensive rats. Am J Physiol Renal Physiol. 2002; 282: F19-25.
44. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002; 39: 799-802.
45. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417: 822-8.
46. Heringer-Walther S, Gembardt F, Perschel FH, et al. The genetic deletion of Mas abolishes salt induced hypertension in mice. Eur J Pharmacol. 2012; 689: 147-53.
47. Zimpelmann J, Burns KD. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol. 2009; 296: F337-46.
48. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 2006; 69: 2212-8.
49. Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int. 2009; 75: 1184-93.
50. Soler MJ, Ye M, Wysocki J, et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009; 296: F398-405.
51. Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol. 2014; 11: 413-26.
52. Tesanovic S, Vinh A, Gaspari TA, et al. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010; 30: 1606-13.
53. Yang JM, Dong M, Meng X, et al. Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arterioscler Thromb Vasc Biol. 2013; 33: 1978-85.
54. van Twist DJ, Kroon AA, de Leeuw PW. Angiotensin-(1-7) as a strategy in the treatment of hypertension? Curr Opin Nephrol Hypertens. 2014; 23: 480-6.
55. Jawien J, Toton-Zuranska J, Gajda M, et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol. 2012; 63: 77-85.